Abstract
Clostridium botulinum is a Gram-positive, spore-forming, anaerobic bacillus that produces a potent neurotoxin. Botulinum neurotoxins (BoNTs) are classified from serotypes A to H, and even though they have similar mechanisms of action, they show preferential hosts. In veterinary medicine, BoNT serotypes C and D are the most important, once several animal species are susceptible to them. Since BoNTs are the most potent toxins known in nature, the best way to control botulism in animals is through vaccination. However, current commercial vaccines are based on inactivated toxins (toxoids) and cells (bacterins) and present many drawbacks, such as a time-consuming production with variable antigen yield and biosafety risks. Recombinant vaccines, especially those produced by Escherichia coli expression system, have proved to be an interesting alternative to overcome these problems. E. coli is a very well-known microorganism that allows the production of large amounts of nontoxic recombinant antigens in a short period using simple culture medium reducing the production complexity and decreasing most of the biosafety risks involved in the process. We describe herein a method for the production of recombinant vaccines for veterinary medicine application, involving initial steps of gene design up to vaccine formulation and evaluation itself.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Smith L (2009) Botulism and vaccines for its prevention. Vaccine 27:D33–D39
Dover N, Barash JR, Hill KK et al (2014) Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis 209:192–202
Simpson LL (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44:167–193
Rodloff AC, Krüger M (2012) Chronic Clostridium botulinum infections in farmers. Anaerobe 18:226–228
Adler M (2012) Structural biology. How a neurotoxin survives. Science 335:928–929
Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535–549
Moreira GMSG, Cunha CEP, Salvarani FM et al (2014) Production of recombinant botulism antigens: a review of expression systems. Anaerobe 28:130–136
Baldwin MR, Tepp WH, Przedpelski A et al (2008) Subunit vaccine against the seven serotypes of botulism. Infect Immun 76:1314–1318
Gil LAF, da Cunha CEP, Moreira GMSG et al (2013) Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D. PLoS One 8:e69692
Cunha CEP, Moreira GMSG, Salvarani FM et al (2014) Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D. Vaccine 32:214–216
Karalewitz AP-A, Barbieri JT (2012) Vaccines against botulism. Curr Opin Microbiol 15:317–324
Pier CL, Tepp WH, Bradshaw M et al (2008) Recombinant holotoxoid vaccine against botulism. Infect Immun 76:437–442
Green M, Sambrook J (2012) Molecular cloning: a laboratory manual, 4th edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Moreira, G.M.S.G., Moreira, C., da Cunha, C.E.P., Mendonça, M., Conceição, F.R. (2016). Recombinant Botulinum Toxoids: A Practical Guide for Production. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1404. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-3389-1_40
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3389-1_40
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-3388-4
Online ISBN: 978-1-4939-3389-1
eBook Packages: Springer Protocols